KYMERA THERAPEUTICS INC Earnings Dividend

KYMERA THERAPEUTICS INC’s revenue jumped 55.5% since last year same period to $34.37Mn in the Q1 2026. On a quarterly growth basis, KYMERA THERAPEUTICS INC has generated 1101.57% jump in its revenue since last 3-months.

KYMERA THERAPEUTICS INC’s net profit fell -5.57% since last year same period to $-69.23Mn in the Q1 2026. On a quarterly growth basis, KYMERA THERAPEUTICS INC has generated 20.45% jump in its net profits since last 3-months.

KYMERA THERAPEUTICS INC’s net profit margin jumped 32.11% since last year same period to -201.47% in the Q1 2026. On a quarterly growth basis, KYMERA THERAPEUTICS INC has generated 93.38% jump in its net profit margins since last 3-months.

KYMERA THERAPEUTICS INC’s earning per share (EPS) estimates for the current quarter stand at -0.82 - a -3.67% fall from last quarter’s estimates.

KYMERA THERAPEUTICS INC’s earning per share (EPS) estimates for the current year stand at -0.82.

KYMERA THERAPEUTICS INC’s earning per share (EPS) jumped 13.41% since last year same period to -0.71 in the Q1 2026. This indicates that the KYMERA THERAPEUTICS INC has generated 13.41% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. KYMERA THERAPEUTICS INC’s return on assets (ROA) stands at -0.17.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. KYMERA THERAPEUTICS INC’s return on equity (ROE) stands at -0.27.